Cytokines, “Depression Due to A General Medical Condition,” and Antidepressant Drugs

  • Raz Yirmiya
  • Joseph Weidenfeld
  • Yehuda Pollak
  • Michal Morag
  • Avraham Morag
  • Ronit Avitsur
  • Ohr Barak
  • 1]Avraham Reichenberg
  • Edna Cohen
  • Yehuda Shavit
  • Haim Ovadia
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 461)

Abstract

Activation of the immune system during various medical conditions produces neural, neuroendocrine, and behavioral effects. The psychological and physiological effects of immune activation resemble many characteristics of depression. The essential features of depression are depressed mood and loss of interest or pleasure in all, or almost all activities (anhedonia). Several associated symptoms are also present, including, appetite disturbance, change in body weight, sleep disturbance, psychomotor disturbance, fatigue, loss of energy, and difficulty in thinking or concentrating (DSM-IV, 1994). Depression is also characterized by specific alterations in the functioning of neurochemical and neuroendocrine systems, including monoaminergic systems and the hypothalamic-pituitary-adrenal (HPA) axis (Brown, Steinberg, & van Praag, 1994; Holsboer, 1995). Most of these psychological and neuroendocrine symptoms appear both in humans and animals during diseases that involve immune activation. Based on these findings, and on several additional lines of evidence that will be presented below, we have recently argued that immune activation is involved in the etiology and symptomatology of depression associated with various medical conditions (Yirmiya, 1997).

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abbey, S. E. & Garfinkel, P. E. (1991). Chronic fatigue syndrome and depression: Cause, effect or covariate. Reviews of Infectious Diseases, 13, S73–83.PubMedGoogle Scholar
  2. Abramowitz, E. S., Baker, A. H., & Fleischer, S. F. (1982). Onset of depressive psychiatric crises and the menstrual cycle. American Journal of Psychiatry, 139(4), 475–478.PubMedGoogle Scholar
  3. Adler, N. E., Boyce, T., Chesney, M. A., Cohen, S., Folkman, S., Khan, R. L., & Syme, S. L. (1994). Socioeconomic status and health. American Psychologist, 49(1), 15–24.PubMedGoogle Scholar
  4. Albrecht, J., Helderman, J. H., Schlesser, M. A., & Rush, A. J. (1985). A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiatry Research, 15, 185–193.PubMedGoogle Scholar
  5. Anderson, N. B. & Armstead, C. A. (1995). Toward understanding the association of socioeconomic status and health: A new challenge for the biopsychosocial approach. Psychosomatic Medicine, 57, 213–225.PubMedGoogle Scholar
  6. Anisman, H., Kokkinidis, L., & Merali, A. (1996). Interleukin-2 decreases accumbal dopamine efflux and responding for rewarding lateral hypothalamic stimulation. Brain Research, 731, 1–11.PubMedGoogle Scholar
  7. Anisman, H., Kokkinidis, L., Borowski, T., & Merali, A. (1998). Differential effects of interleukin (IL)-l, IL-2, and IL-6 on responding for rewarding lateral hypothalamic stimulation. Brain Research, 779, 177–187.PubMedGoogle Scholar
  8. Arenzana-Seisdedos, F. & Virelizer, J. L. (1983). Interferons as macrophage-activating factors. II. Enhanced secretion of interleukin-1 by lipopolysaccharide-stimulated human monocytes. European Journal of Immunology, 13, 437–440.PubMedGoogle Scholar
  9. Arvin, B., Neville, L. F., Barone, F. C, & Feuerstein, G. Z. (1996). The role of inflammation and cytokines in brain injury. Neuroscience and Biobehavioral Reviews, 20, 445–452.PubMedGoogle Scholar
  10. Aubert, A., Vega, G, Dantzer, R., & Goodall, G. (1995). Pyrogens specifically disrupt the acquisition of a task involving cognitive processing in the rat. Brain Behavior and Immunity, 9, 129–148.Google Scholar
  11. Aubert, A. & Dantzer, R. (1998). Effects of lipopolysaccharide on taste reactivity in rats. Neuroim-munomodulation, 5, 3.Google Scholar
  12. Audus, K. L. & Gordon, M. A. (1982). Tricyclic antidepressant effects on the murine lymphocyte mitogen response. Journal of Immunopharmacology, 4, 13–27.PubMedGoogle Scholar
  13. Avitsur, R., Pollak, Y., & Yirmiya, R. (1997). Different receptor mechanisms mediate the effects of endotoxin and interleukin-1 on female sexual behavior. Brain Research, 773, 149–161.PubMedGoogle Scholar
  14. Avitsur, R., Cohen, E., & Yirmiya, R. (1998). Effects of interleukin-1 on sexual attractivity in a model of sickness behavior. Physiology and Behavior, 63, 25–30.Google Scholar
  15. Ayuso, J. L. (1994). Use of psychotropic drugs in patients with HIV infection. Drugs, 47(4), 599–610.PubMedGoogle Scholar
  16. Badia-Elder, N., Kiefer, S. W., & Dess, N. K. (1996). Taste reactivity in rats selectively bred for high vs. low saccharin consumption. Physiology and Behavior, 59, 749–755.PubMedGoogle Scholar
  17. Barden, N., Reul, J. M. H. M., & Holsboer, F. (1995). Do antidepressants stabilize mood through actions on the hypothalamic-pituitary-adrenocortical system? Trends in Neurosciences, 18, 6–11.PubMedGoogle Scholar
  18. Bauer, J., Hohagen, F., Gimmel, E., Bruns, F., Lis, S., Krieger, S., Ambach, W., Guthmann, A., Grunze, H., Fritsch-Montero, R., Weissbach, A., Ganter, U., Frommnerger, U., Riemann, D., & Berger, M. (1995). Induction of cytokines synthesis and fever suppresses REM sleep and improves mood in patients with major depression. Biological Psychiatry, 38, 611–621.PubMedGoogle Scholar
  19. Beers, D. R., Henkel, J. S., Kesner, R. P., & Stroop, W. G. (1995). Spatial recognition memory deficits without notable CNS pathology in rats following herpes simplex encephalitis. Journal of the Neurological Sciences, 131, 119–127.PubMedGoogle Scholar
  20. Besedovsky, H. O. & Del-Rey, A. (1996). Immune-neuro-endocrine interactions: facts and hypotheses. Endocrine Reviews, 17, 64–102.PubMedGoogle Scholar
  21. Bianchi, M., Sacerdote, P., & Panerai, A. E. (1994a). Fluoxetin reduces inflammatory edema in the rat: Involvement of the pituitary-adrenal axis. European Journal of Pharmacology, 263, 81–84.PubMedGoogle Scholar
  22. Bianchi, M., Sacerdote, P., & Panerai, A. E. (1994b). Chlomipramine differentially affects inflammatory edema and pain in the rat. Pharmacology, Biochemistry, and Behavior, 4, 1037–1040.Google Scholar
  23. Bianchi, M., Rossoni, G., Sacerdote, P., Panerai, A. E., & Berti, F. (1995). Effects of clomipramine and fluoxetin on subcutaneous carrageenin-induced inflammation in the rat. Inflammation Research, 44, 466–469.PubMedGoogle Scholar
  24. Bluthe, R. M., Dantzer, R., & Kelley, K.W. (1991). Interleukin-1 mediates behavioral but not metabolic effects of tumor necrosis factor alpha in mice. European Journal of Pharmacology, 209, 281–283.PubMedGoogle Scholar
  25. Bluthe, R. M., Crestani, F., Kelley, K. W., & Dantzer, R. (1992). Mechanisms of the behavioral effects of interleukin 1. Role of prostaglandins and CRF. Annals of The New York Academy of Sciences, 650, 268–275.PubMedGoogle Scholar
  26. Bluthe, R. M., Dantzer, R., & Kelley, K. W. (1997). Central mediation of the effects of interleukin-1 on social exploration and body weight in mice. Psychoneuroendocrinology, 22, 1–11.PubMedGoogle Scholar
  27. Bode, L., Zimmerman, W., Ferszt, R., Steinbach, F., & Ludwig, H. (1995). Borna disease virus genome transcribed and expressed in psychiatric patients. Nature Medicine, 1, 232–236.PubMedGoogle Scholar
  28. Bode, L., Durrwald, R., Rantam, F. A., Ferszt, R., & Ludwig, H. (1996). First isolation of infectious human Borna disease virus from patients with mood disorders. Molecular Psychiatry, 1, 200–212.PubMedGoogle Scholar
  29. Borowski, T., Kokkinidis, L., Merali, A., & Anisman, H. (1997). Behavioral and central monoamine alterations induced by interleukin-1, interleukin-6, and lipopolysaccharide. Society for Neuroscience Abstracts, 23, 1508.Google Scholar
  30. Brady, L. S., Whitfield, H. J., Fox, R. J., Gold, P. W., & Herkenham, M. (1991). Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Journal of Clinical Investigation, 87, 831–837.PubMedGoogle Scholar
  31. Brady, L. S., Gold, P. W., Herkenham, M., Lynn, A. B., & Whitfield, H. J. (1992). The antidepressants fluoxetine, idazoxan, and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Research, 572, 117–125.PubMedGoogle Scholar
  32. Breuille, D., Farge, M. C, Rose, F., Arnel, M., Attaix, D., & Obled, C. (1993). Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis. American Journal of Physiology, 265, E660–E666.PubMedGoogle Scholar
  33. Brown, S. L., Steinberg, R. L., & van Praag, H. M. (1994). The pathogenesis of depression: reconsideration of neurotransmitter data. In J. A. Den Boer & J. M. Sitsen (Eds.), Handbook of Depression and Anxiety: A Biological Approach (pp. 529–542). New York: Marcel Dekker, Inc.Google Scholar
  34. Bruce, M. L., Takeuchi, D. T., & Leaf, P. J. (1991). Poverty and psychiatric status. Archives of General Psychiatry, 48, 470–474.PubMedGoogle Scholar
  35. Buchwald, D. & Komaroff, A. L. (1991). Review of laboratory findings for patients with chronic fatigue syndrome. Reviews of Infectious Diseases, 13, 12–18.Google Scholar
  36. Burnet, P. W. J., Michelson, D., Smith, M. A., Gold, P. W., & Sternberg, E. M. (1994). The effect of chronic imipramine administration on the densities of 5-HT1A and 5-HT2 receptors and the abundances of 5-HT receptor and transporter mRNA in the cortex, hippocampus, and dorsal raphe of three strains of rat. Brain Research, 638, 311–324.PubMedGoogle Scholar
  37. Cannon, J. G. & Dinarello, C. A. (1985). Increased plasma interleukin-1 activity in woman after ovulation. Science, 227, 1247–1249.PubMedGoogle Scholar
  38. Cappel, R., Gregoire, E., Thiry, L., & Sprecher, S. (1978). Antibody and cell-mediated immunity to herpes simplex virus in psychotic depression. Journal of Clinical Psychiatry, 39, 266–268.PubMedGoogle Scholar
  39. Carroll, B. J., Martin, F. I. R., & Davies, B. (1968). Resistance to suppression by dexamethasone of plasma 11-hydroxycorticosterone levels in severe depressive illness. British Medical Journal, 3, 285–287.PubMedGoogle Scholar
  40. Carroll, B. J., Curtis, G. C, & Mendels, J. (1976). Neuroendocrine regulation in depression. I. Limbic system adrenocortical dysfunction. Archives of General Psychiatry, 33, 1039–1044.PubMedGoogle Scholar
  41. Cavallo, M. G., Pozzini, P., & Thorpe, R. (1993). Cytokines and autoimmunity. Clinical and Experimental Immunology, 96, 1–7.Google Scholar
  42. Chochinov, H. M., Wilson, K. G., Enns, M., & Lander, S. (1994). Prevalence of depression in the terminally ill: Effects of diagnostic criteria and symptom threshold judgments. American Journal of Psychiatry, 4, 537–540.Google Scholar
  43. Cleare, A. J., Bearn, J., Allain, T., McGregor, A., Wessely, S., Murray, R. M., & O’Keane, V. (1995). Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. Journal of Affective Disorders, 34, 283–289.PubMedGoogle Scholar
  44. Cohen, S. (1995). Psychological stress and susceptibility to upper respiratory infections. American Journal of Respiratory and Critical Care Medicine 152, 53–58.Google Scholar
  45. Connor, T. J. & Leonard, B. E. (1998). Depression, stress and immunological activation: the role of cytokines in depressive disorders. Life Sciences, 62, 583–606.PubMedGoogle Scholar
  46. Cox, S. M., King, M. R., Casey, M. L., & Macdonald, P. C. (1993). Interleukin-lβ,-lα, and-6 and prostaglandins in vaginal cervical fluids of pregnant women before and during labor. Journal of Clinical Endocrinology and Metabolism, 77, 805–815.PubMedGoogle Scholar
  47. Cunningham, A. J., Murray, C. A., O’Neill, L. A. J., Lynch, M. A., & O’Connor, J. J. (1996). Interleukin-lβ (IL-lβ) and tumour necrosis factor (TNF) inhibit long-term potentiation in the rat dentate gyrus in vitro. Neuroscience Letters, 203, 17–20.PubMedGoogle Scholar
  48. Dantzer, R., Bluthe, R. M., Aubert, A., Goodall, G., Bret-Dibat, J. L., Kent, S., Goujon, E., Laye, S., Parnet, P., & Kelley, K. W. (1996). Cytokine actions on behavior. In N. J. Rothwell (Ed.), Cytokines in the nervous system (pp. 117–144). New York: R. G. Landes Company and Chapman & Hall.Google Scholar
  49. Day, H. E. W. & Akil, H. (1996). Differential pattern of c-fos mRNA in rat brain following central and systemic administration of interleukin-1 beta: Implications for mechanisms of action. Neuroendocrinology, 63, 207–218.PubMedGoogle Scholar
  50. Denburg, S. D., Carbotte, R. M., & Denburg, J. A. (1997). Psychological aspects of systemic lupus erythematosus: Cognitive Function, mood, and self-report. Journal of Rheumatology, 24, 998–1003.PubMedGoogle Scholar
  51. Dess, N. K. (1993). Saccharin’s aversive taste in rats: Evidence and implications. Neuroscience and Biobehavioral Reviews, 17, 359–372.PubMedGoogle Scholar
  52. Dinarello, C. A. & Wolff, S. M. (1993). The role of interleukin-1 in disease. New England Journal of Medicine, 328, 106–113.Google Scholar
  53. Dohrenwend, B. P. (1973). Social status and stressful life events. Journal of Personality and Social Psychology, 28, 225–235.PubMedGoogle Scholar
  54. DSM-IV, Diagnostic and Statistical Manual of Mental Disorders Fourth Edition. (1994). Washington, DC: American Psychiatric Association.Google Scholar
  55. Dunbar, P. R., Hill, J., Neale, T. J., & Mellsop, G. W. (1992). Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia. Psychological Medicine, 22, 1051–1057.PubMedGoogle Scholar
  56. Dunn, A. J. & Welch, J. (1991). Stress-and endotoxin-induced increases in brain tryptophan and serotonin metabolism depend on sympathetic nervous system activity. Journal of Neurochemistry, 57, 1615–1622.PubMedGoogle Scholar
  57. Dunn, A. J. & Wang, J. (1995). Cytokine effects on CNS biogenic amines. Neuroimmunomodulation, 2, 319–328.PubMedGoogle Scholar
  58. Dunn, A. J., Chapman, Y., & Antoon, M. (1993). Endotoxin-induced behavioral changes of mice in the multicompartment chamber are distinct from those of interleukin-1. Neuroscience Research Communications, 10, 63–69.Google Scholar
  59. Eisen, J. N., Irwin, J., Quay, J., & Livnat, S. (1989). The effect of antidepressants on immune function in mice. Biological Psychiatry, 26, 805–817.PubMedGoogle Scholar
  60. Fent, K. & Zbinden, G. (1987). Toxicity of interferon and interleukin. Trends in Pharmacological Sciences, 8, 101–105.Google Scholar
  61. Foley, F. W, Traugott, U, LaRocca, N. G, Smith, C. R., Perlman, K. R., Caruso, L. S., & Scheinberg, L. C. (1992). A prospective study of depression and immune dysregulation in multiple sclerosis. Archives of Neurology, 49, 238–244.PubMedGoogle Scholar
  62. Gibertini, M. (1996). IL-1 beta impairs relational but not procedural rodent learning in a water maze task. Advances in Experimental Medicine and Biology, 402, 207–217.PubMedGoogle Scholar
  63. Gibertini, M., Newton, C, Friedman, H., & Klein, T. W. (1995). Spatial learning impairment in mice with legionella pneumophila or administered exogenous interleukin-1-beta. Brain, Behavior, and Immunity, 9, 113–128.PubMedGoogle Scholar
  64. Gold, P. W, Chrousos, G, Kellner, G, Post, R., Roy, A., Auerginos, P., Schulte, H., Oldfield, E., & Loriaux, D. L. (1984). Psychiatric implications of basic and clinical studies with corticotropin releasing factor. American Journal of Psychiatry, 141, 619–627.PubMedGoogle Scholar
  65. Gottfries, C. G. (1997). Recognition and management of depression in the elderly. International Clinical Psychopharmacology, 12(7), S31–S36.PubMedGoogle Scholar
  66. Goujon, E., Parnet, P., Laye, S., Combe, C, Kelley, K. W, & Dantzer, R. (1995). Stress downregulates lipopolysaccharide-induced expression of proinflammatory cytokines in the spleen, pituitary, and brain of mice. Brain, Behavior, and Immunity, 9, 292–303.PubMedGoogle Scholar
  67. Granger, D. A., Hood, K. E., Ikeda, S. C, Reed, C. L., Jones, B. C, & Block, M. L. (1997). Effects of peripheral immune activation on social behavior and adrenocortical activity in aggressive mice: genotype environment interactions. Aggressive Behavior, 23, 93–105.Google Scholar
  68. Greenwood, R. (1987). Residual mental disorders after herpesvirus infections. In E. Kurstak, Z. J. Lipowski, & P. V. Morozov (Eds.), Viruses, Immunity, and Mental Disorders (pp. 65–80). New York: Plenum.Google Scholar
  69. Grill, J. J. & Norgren, R. (1978). The taste reactivity test. II. Mimetic responses to gustatory stimuli in chronic thalamic and chronic decerebrate rats. Brain Research, 143, 281–297.PubMedGoogle Scholar
  70. Grossman, C. J. (1985). Interactions between the gonadal steroids and the immune system. Science, 227, 257–261.PubMedGoogle Scholar
  71. Hall, S. & Smith, A. P. (1996a). Investigating the effects and aftereffects of naturally occurring upper respiratory tract illnesses on mood and performance. Physiology and Behavior, 59, 569–577.PubMedGoogle Scholar
  72. Hall, S. & Smith, A. P. (1996b). Behavioral effects of infectious mononucleosis. Neuropsychobiology, 33, 202–209.PubMedGoogle Scholar
  73. Hart, B. (1988). Biological basis of the behavior of sick animals. Neuroscience and Biobehavioral Reviews, 12, 123–37.PubMedGoogle Scholar
  74. Hendler, N. (1987). Infectious mononucleosis and psychiatric disorders. In E. Kurstak, Z. J. Lipowski, & P. V. Morozov (Eds.), Viruses, Immunity, and Mental Disorders (pp. 81–94). New York: Plenum.Google Scholar
  75. Herbert, T. B. & Cohen, S. (1993). Depression and immunity: A meta-analytic review. Psychological Bulletin, 3, 472–486.Google Scholar
  76. Heyser, C. X, Masliah, E., Samimi, A., Campbell, I. L., & Gold, L. H. (1997). Progressive decline in avoidance learning paralleled by inflammatory neurodegeneration in transgenic mice expressing interleukin-6 in the brain. Proceedings of the National Academy of Sciences of the United States of America, 94, 1500–1505.PubMedGoogle Scholar
  77. Hickie, I. & Lloyd, A. (1995). Are cytokines associated with neuropsychiatric syndromes in humans? International Journal of Immunopharmacology, 17, 677–683.PubMedGoogle Scholar
  78. Holsboer, F. (1995). Neuroendocrinology of mood disorders. In F. E. Bloom & D. J. Kupfer (Eds.), Psychopharmacology: The Fourth Generation of Progress (pp. 957–969). New York: Raven Press.Google Scholar
  79. Holsboer, F. & Barden, N. (1996). Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocrine Reviews, 17, 187–205.PubMedGoogle Scholar
  80. Holsboer, F., Liebel, R., & Hofschuster, E. (1982). Repeated dexamethasone test during depressive illness: normalization of test result compared with clinical improvement. Journal of Affective Disorders, 4, 93–101.PubMedGoogle Scholar
  81. Hutchinson, G. A., Nehall, J. E., & Simeon, D. T. (1996). Psychiatric disorders in systemic lupus erythemato-sus. West Indian Medical Journal, 45, 48–50.PubMedGoogle Scholar
  82. Isometsa, E.T., Aro, H. M., Henriksson, M. M., Heikkinen, M. E., & Lonnqvist, J. K. (1994). Suicide and major depression in different treatment settings. Journal of Clinical Psychiatry, 55, 523–527.PubMedGoogle Scholar
  83. Joffe, R. T., Lippert, G. P., Gray, T. A., Sawa, G., & Horvath, A. (1987). Mood disorder and multiple sclerosis. Archives of Neurology, 44, 376–378.PubMedGoogle Scholar
  84. Johnson, R. W., Propes, M. J., & Shavit, Y. (1996). Corticosterone modulates the behavioral and metabolic effects of lipopolysaccharide. American Journal of Physiology, 270, R192–R198.PubMedGoogle Scholar
  85. Katon, W. & Sullivan, M. D. (1990). Depression and chronic medical illness. Journal of Clinical Psychiatry, 51, 3–11.PubMedGoogle Scholar
  86. Katsuki, H., Nakai, S., Hirai, Y, Akaji, K., Kiso, Y, & Satoh, M. (1990). Interleukin-lβ inhibits long-term potentiation in the CA3 region of mouse hippocampal slices. European Journal of Pharmacology, 191, 323–326.Google Scholar
  87. Kavaliers, M., Colwell, D. D., & Galea, L. A. M. (1995). Parasitic infection impairs spatial learning in mice. Animal Behaviour, 50, 223–229.Google Scholar
  88. Kent, S., Bluthe, R. M., Kelley, K. W., & Dantzer, R. (1992a). Sickness behavior as a new target for drug development. Trends in Pharmacological Sciences, 13, 24–28.PubMedGoogle Scholar
  89. Kent, S., Bluthe, R. M., Dantzer, R., Hardwick, A. J., Kelley, K. W., Rothwell, N. X, & Vannice, X L. (1992b). Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin-1. Proceedings of the National Academy of Sciences of the United States of America, 89, 9117–9120.PubMedGoogle Scholar
  90. Kiecolt-Glaser, J. K. & Glaser, R. (1991). Stress and immune function in humans. In R. Ader, D. L. Feiten, & N. Cohen (Eds.), Psychoneroimmunology (pp. 849–867). San Diego: Academic Press.Google Scholar
  91. Klonoff, D. C. (1992). Chronic fatigue syndrome. Clinical infectious diseases, 15, 812–823.PubMedGoogle Scholar
  92. Komaroff, A. L. & Buchwald, D. S. (1991). Symptoms and signs of chronic fatigue syndrome. Reviews of Infectious Diseases, 13, 8–11.Google Scholar
  93. Komaroff, A. L. & Buchwald, D. S. (1998). Chronic fatigue syndrome: an update. Annual Review of Medicine, 49, 1–13.PubMedGoogle Scholar
  94. Komaroff, A. L., Fagioli, L. R., Geiger, A. M., Doolittle, T. H., Lee, X, Kornish, X, Gleit, M. A., & Guerriero, R. T. (1996). An examination of the working case definition of chronic fatigue syndrome. American Journal of Medicine, 100, 56–64.PubMedGoogle Scholar
  95. Kozak, W., Poli, V., Soszynski, D., Conn, C. A., Leon, L. R., & Kluger, M. (1996). Sickness behavior in mice deficient in interleukin-6 during turpentine abscess and influenza pneumonitis. American Journal of Physiology, 272, R621–R630.Google Scholar
  96. Kozak, W., Soszynski, D., Rudolph, K., Conn, C. A., & Kluger, M. (1997). Dietary n-3 fatty acids differentially affect sickness behavior in mice during local and systemic inflammation. American Journal of Physiology, 272, R1298–R1307.PubMedGoogle Scholar
  97. Krueger, J. M. & Majde, J. A. (1994). Microbial products and cytokines in sleep and fever regulation. Critical Reviews in Immunology, 14, 355–379.PubMedGoogle Scholar
  98. Krueger, J. M., Takahashi, S., Kapas, L., Bredow, S., Roky, R., Fang, J., Floyd, R., Renegar, K. B., Guha-Thakurta, N., Novitsky, S., & Obal, F. (1995). Cytokines in sleep regulation. Advances in Neuroimmunology, 5, 171–188.PubMedGoogle Scholar
  99. Kubera, M., Symbirtsev, A., Basta-Kaim, A., Borycz, J., Roman, A., Papp, M., & Claesson, M. (1996). Effect of chronic treatment with imipramine on interleukin-1 and interleukin-2 production by splenocytes obtained from rats subjected to chronic mild stress model of depression. Polish Journal of Pharmacology, 48, 503–506.PubMedGoogle Scholar
  100. Laghrissi-Thode, F., Pollock, B. G., Szanto, K., & Reynolds, C. F. (1996). Depression and suicide in medically ill patients. Current Opinion in Psychiatry, 9, 137–140.Google Scholar
  101. Landmann, R., Schaub, B., Link, S., & Wacker, H. R. (1997). Unaltered monocyte function in patients with major depression before and after three months of antidepressive therapy. Biological Psychiatry, 41, 675–681.PubMedGoogle Scholar
  102. Laruelle, M., Seghers, A., Goffinet, S., Bouchez, S., & Legros, J. J. (1990). Plasmatic vasopressin neurophysin in depression: Basic levels and relations with HPA axis. Biological Psychiatry, 27, 1249–1263.PubMedGoogle Scholar
  103. Lauritzen, L., Bjerg Bendsen, B., Vilmar, T., Bjerg Bendsen, E., Lunde, M., & Bech, P. (1994). Post-stroke depression: combined treatment with imipramine or desipramine and mianserin. Psychopharmacology, 114, 119–122.PubMedGoogle Scholar
  104. Leonard, B. E. (1994). Effect of antidepressants on specific neurotransmitters: Are such effects relevant to the therapeutic actions? In J. A. den Boer & J. M. Siten (Eds.), Handbook of depression and anxiety: A biological approach (pp. 379–404). New York: Marcel Dekker, Inc.Google Scholar
  105. Levenson, J. L. & Fallon, H. J. (1993). Fluoxetine treatment of depression caused by interferon-alpha. American Journal of Gastroenterology, 88(5), 760–761.PubMedGoogle Scholar
  106. Li, Q., Levy, A. D., Cabrera, T. M, Brownfield, M. S., Battaglia, G., & Van de Kar, L. D. (1993). Long-term fluoxetine, but not desipramine, inhibits the ACTH and oxytocin responses to the 5-HT 1A agonist, 8-OH-DPAT, in male rats. Brain Research, 630, 148–156.PubMedGoogle Scholar
  107. Licinio, J., Kling, M. A., & Hauser, P. (1998). Cytokines and brain function: relevance to interferon-alpha-induced mood and cognitive changes. Seminars in Oncology, 25(1), 30–38.PubMedGoogle Scholar
  108. Lieb, J. & Karmali, R. (1983). Elevated levels of prostaglandin E2 and thromboxane B2 in depression. Prostaglandins and Leukotrienes in Medicine, 10, 361–368.Google Scholar
  109. Lim, L., Ron, M. A., Ormerod, I. E., David, J., Miller, D. H., Logsdail, S. J., Walport, M. J., & Harding, A. E. (1988). Psychiatric and neurological manifestations in systemic lupus erythematosus. Quarterly Journal of Medicine, 66, 27–38.PubMedGoogle Scholar
  110. Linkowski, P., Mendlewicz, 1, Leclercq, R., Brasseur, M., Hubain, P., Goldstein, J., Copinschi, G., & van Cauter, E. (1985). The 24-hr profile of adrenocorticotropin and cortisol in major depressive illness. Journal of Clinical Endocrinology and Metabolism, 61, 429–438.PubMedGoogle Scholar
  111. Linnoila, M., Whorton, R., Rubinow, D. R., Cowdry, R. W., Ninan, P. T., & Waters, R. N. (1983). CSF prostaglandin levels in depressed and schizophrenic patients. Archives of General Psychiatry, 40, 405–406.PubMedGoogle Scholar
  112. Linthorst, A. C. E., Flachskamm, G, Holsboer, F., & Reul, J. M. H. M. (1995a). Intraperitoneal administration of bacterial endotoxin enhances noradrenergic neurotransmission in the rat preoptic area: relationship with body temperature and hypothalamic-pituitary-adrenocortical axis activity. European Journal of Neuroscience, 7, 2418–2430.PubMedGoogle Scholar
  113. Linthorst, A. C. E., Flachskamm, C, Muller-Preuss, P., Holsboer, F., & Reul, J. M. H. M. (1995b). Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: an in vivo microdialysis study. Journal of Neuroscience, 15, 2920–2934.PubMedGoogle Scholar
  114. Lycke, E., Norrby, R., & Roos, B. E. (1974). A serological study on mentally ill patients with particular reference to prevalence of herpes simplex virus infections. British Journal of Psychiatry, 124, 273.PubMedGoogle Scholar
  115. Lyketsos, C. G., Steele, C, Baker, L., Galik, E., Kopunek, S., Steinberg, M., & Warren, A. (1997). Major and minor depression in Alzheimer’s disease: prevalence and impact. Journal of Neuropsychiatry and Clinical Neurosciences, 9(4), 556–561.PubMedGoogle Scholar
  116. Lynch, E. A., Dinarello, C. A., & Cannon, J. G. (1994). Gender differences in IL-lα, IL-lβ, and IL-1 receptor antagonist secretion from mononuclear cells and urinary excretion. Journal of Immunology, 153, 300–306.Google Scholar
  117. Maes, M. (1995). Evidence for an immune response in major depression: A review and hypothesis. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 19, 11–38.PubMedGoogle Scholar
  118. Maes, M., DeJonckheere, C, Vandervorst, C, Schotte, G, Cosyns, P., Raus, J., & Suy, E. (1991). Abnormal pituitary function during melancholia: Reduced alpha melanocyte stimulating hormone secretion and increased intact ACTH non-suppression. Journal of Affective Diseases, 22, 149–157.Google Scholar
  119. Maes, M., Lambrechts, J., Bosmans, E., Jacobs, J., Suy, E., Vandervorst, G, De Jockheere, G, Minner, B., & Raus, J. (1992a). Evidence for systemic immune activation during depression: results of leukocyte enumeration by flow cytometry in conjunction with monoclonal antibody staining. Psychological Medicine, 22, 45–53.PubMedGoogle Scholar
  120. Maes, M., Scharpe, S., Van Grootel, L., Uyttenbroeck, W., Cooreman, W., Cosyns, P., & Suy, E. (1992b). Higher alpha-1-antitrypsin, haptoglobin, ceruloplasmin, and lower retinol binding protein plasma levels during depression: further evidence for the existence of an inflammatory response during that illness. Journal of Affective Disorders, 24, 183–192.PubMedGoogle Scholar
  121. Maes, M., Bosmans, E., Meltzer, H. Y., Scharpe, S., & Suy, E. (1993). Interleukin-lβ—A Putative Mediator of HPA Axis Hyperactivity in Major Depression. American Journal of Psychiatry, 150, 1189–1193.PubMedGoogle Scholar
  122. Maes, M., Scharpe, S., Meltzer, H. Y., Okayli, G., D’Hondt, P., & Cosyns, P. (1994). Increased neopterin and interferon gamma secretion and lower L-tryptophan levels in major depression: further evidence for immune activation in severe depression. Psychiatry Research, 54, 143–160.PubMedGoogle Scholar
  123. Maes, M., Meltzer, H. Y, Bosmans, E., Bergmans, R., Vandoolaeghe, E., Ranjan, R., & Desnyder, R. (1995a). Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2, and transferrin receptor in major depression. Journal of Affective Disorders, 34, 301–309.PubMedGoogle Scholar
  124. Maes, M., Scharpe, S., Neels, H., Wauters, A., Van Gastel, A., & Cosyns, P. (1995b). Total serum protein and serum protein fractions in major depression. Journal of Affective Disorders, 34, 61–69.PubMedGoogle Scholar
  125. Maes, M., Smith, R., & Scharpe, S. (1995c). The monocyte T-lymphocyte hypothesis of major depression. Psychoneuroendocrinology, 20, 111–116.PubMedGoogle Scholar
  126. Maes, M., Bosmans, E., De Jongh, R., Kenis, G., Vandoolaeghe, E., & Neels, H. (1997a). Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine, 9, 853–858.PubMedGoogle Scholar
  127. Maes, M., Vandoolaeghe, E., Van Hunsel, F., Bril, T., Demedts, P., Wauters, A., & Neels, H. (1997b). Immune disturbances in treatment-resistant depression: modulation by antidepressive treatment. Human Psychopharmacology, 12, 153–162.Google Scholar
  128. Magner, M. B. (1991). Psychiatric morbidity in outpatients with systemic lupus erythematosus. South African Medical Journal, 80, 291–293.PubMedGoogle Scholar
  129. Maier, S. F. & Watkins, L. R. (1998). Cytokines for psychologists: Implications of bi-directional immune-to-brain communication for understanding behavior, mood, and cognition. Psychological Review, 105, 83–107.PubMedGoogle Scholar
  130. Maj, M. (1996). Depressive syndromes and symptoms in subjects with human immunodefficiency virus (HIV) infection. British Journal of Psychiatry, 168, 117–122.Google Scholar
  131. Marshal, P. S. (1993). Allergy and depression: A neurochemical threshold model of the relation between the illnesses. Psychological Bulletin, 113, 23–43.Google Scholar
  132. Mathew, R. J. & Weinman, M. L. (1982). Sexual dysfunctions in depression. Archives of Sexual Behavior, 11, 323–328.PubMedGoogle Scholar
  133. McDonald, E. M., Mann, A. H., & Thomas, H. G(1987). Interferons as mediators of psychiatric morbidity: An investigation in a trial of recombinant α-interferon in hepatitis-B carriers. Lancet, 2, 1175–1179.PubMedGoogle Scholar
  134. McGeer, P. L. & McGeer, E. G. (1995). The inflammatory response system of brain: implications for therapy of Alzheimer and other neurodegenerative diseases. Brain Research Reviews, 21, 195–218.PubMedGoogle Scholar
  135. Meijer, A., Zakay-Rones, Z., & Morag, A. (1988). Post-influenzal psychiatric disorder in adolescents. Acta Psychiatrica Scandinavica, 78, 176–181.PubMedGoogle Scholar
  136. Mendez, M. F., Martin, R. J., Smyth, K. A., & Whitehouse, P. J. (1990). Psychiatric symptoms associated with Alzheimer’s disease. Journal of Neuropsychiatry and Clinical Neurosciences, 2(1), 28–33.PubMedGoogle Scholar
  137. Meyers, G A. & Valentine, A. D. (1995). Neurologic and psychiatric adverse effects of immunological therapy. CNS Drugs, 3, 56–68.Google Scholar
  138. Meyers, G A., Valentine, A. D., Wong, F. G L., & Leeds, N. E. (1994). Reversible neurotoxicity of interleukin-2 and tumor necrosis factor: Correlation of SPECT with neurophysiological testing. Journal of Neuropsychiatry and Clinical Neurosciences, 6, 285–288.PubMedGoogle Scholar
  139. Meyerson, B. J. & Lindstrom, L. H. (1973). Sexual motivation in the female rat. Acta Physiologica Scandinavica, 389, 1–80.Google Scholar
  140. Miller, N. E. (1964). Some psychophysiological studies of motivation and of the behavioral effects of illness. Bulletin of the British Psychological Society, 17, 1–20.Google Scholar
  141. Miller, A. H., Asnis, G. M., Van Praag, H. M., & Norin, A. J. (1986). Influence of desmethylimipramine on natural killer cell activity. Psychiatry Research, 19, 9–15.PubMedGoogle Scholar
  142. Minden, S. L. & Schiffer, R. B. (1990). Affective disorders in multiple sclerosis: Review and recommendations for clinical research. Archives of Neurology, 47, 98–104.PubMedGoogle Scholar
  143. Minden, S. L., Orav, J., & Reich, P. (1987). Depression in multiple sclerosis. General Hospital Psychiatry, 9, 426–434.PubMedGoogle Scholar
  144. Mohr, D. C., Goodkin, D. E., Likosky, W., Gatto, N., Baumann, K. A., & Rudick, R. A. (1997). Treatment of depression improves adherence to interferon β-Ib therapy for multiple sclerosis. Archives of Neurology, 54(5), 531–533.PubMedGoogle Scholar
  145. Montgomery, S. A. (1994). Antidepressants in long-term treatment. Annual Review of Medicine, 45, 447–457.PubMedGoogle Scholar
  146. Morag, M., Yirmiya, R., Lerer, B., & Morag, A. (in press). Influence of socioeconomic status on behavioral, emotional, and cognitive effects of rubella vaccination: A prospective, double blind sudy. Psychoneu-roendocrinology.Google Scholar
  147. Mrak, R. E., Sheng, J. G., & Griffin, S. T. (1995). Glial cytokines in Alzheimer’s disease: review and pathogenic implications. Human Pathology, 26(8), 816–823.PubMedGoogle Scholar
  148. Muller, N., Hofschuster, E., Ackenheil, M., Mempel, W., & Eckstein, R. (1993). Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis. Progress in Neuropsychopharmacology and Biological Psychiatry, 17, 713–730.Google Scholar
  149. Murphy, J. M., Olivier, D. C., Monson, R. R., Sobol, A. M., Federman, E. B., & Leighton, A. H. (1991). Depression and anxiety in relation to social status. Archives of General Psychiatry, 48, 223–229.PubMedGoogle Scholar
  150. Newman, M. E., Shapira, B., & Lerer, B. (1992). Regulation of 5-hydroxytryptamine 1A receptor function in rat hippocampus by short-and long-term administration of 5-hydroxytryptamine agonist and antidepressants. Journal of Pharmacology and Experimental Therapeutics, 260, 16–20.PubMedGoogle Scholar
  151. Niiranen, A., Laaksonen, R., Iivanainen, M., Mattson, K., Fakkila, M., & Cantell, K. (1988). Behavioral assessment of patients treated with alpha-interferon. Acta Psychiatrica Scandinavica, 78, 622–626.PubMedGoogle Scholar
  152. Oitzl, M. S., van Oers, H., Schobitz, B., & de Kloet, E. R. (1993). Interleukin-lβ, but not interleukin-6, impairs spatial navigation learning. Brain Research, 613, 160–163.PubMedGoogle Scholar
  153. Okanoue, T., Sakamoto, S., Itoh, Y., Minami, M., Yasui, K., Sakamoto, M., Nishioji, K., Katagishi, T., Nakagawa, Y, Tada, H., Sawa, Y, Mizuno, M., Kagawa, K., & Kashima, K. (1996). Side effects of high-dose interferon therapy for chronic hepatitis C. Journal of Hepatology 25, 283–291.PubMedGoogle Scholar
  154. Owens, M. J. & Nemeroff, C. B. (1993). The role of CRF in the pathophysiology of affective disorders: laboratory and clinical studies. In W. W. Vale (Ed.), Ciba Foundation Symposium on Corticotropin Releasing Factor, 172 (pp. 193–316). New York: John Wiley.Google Scholar
  155. Parker, J., Smarr, K., Anderson, S., Hewett, J., Walker, S., Bridges, A., & Caldwell, W. (1992). Relationship of changes in helplessness and depression to disease activity in rheumatoid arthritis. Journal of Rheumatology, 19, 1901–1905.PubMedGoogle Scholar
  156. Parry, B. L. (1995). Mood disorders linked to the reproductive cycle in women. In F. E. Bloom & D. J. Kupfer (Eds.), Psychopharmacology: The fourth Generation of Progress (pp. 1029–1042). New York: Raven Press.Google Scholar
  157. Pavol, M. A., Meyers, C. A., Rexer, J. L., Valentine, A. D., Mattis, P. J., & Talpaz, M. (1995). Pattern of neurobehavioral deficits associated with interferon a therapy for leukemia. Neurology, 45, 947–950.PubMedGoogle Scholar
  158. Pincus,, Griffith, J., Pearce, S., & Isenberg, D. (1996). Prevalence of self-reported depression in patients with rheumatoid arthritis. British Journal of Rheumatology, 35, 879–883.PubMedGoogle Scholar
  159. Plata-Salaman, C. R. (1996). Anorexia during acute and chronic disease. Nutrition, 12, 69–78.PubMedGoogle Scholar
  160. Plata-Salaman, C. R. (1998). Cytokines and anorexia: a brief overview. Seminars in Oncology, 25(1), 64–72.PubMedGoogle Scholar
  161. Pollak, Y, Avitsur, R., Canaan, R., & Yirmiya, R. (1998). Central al adrenergic receptors are involved in mediating IL-1 induced sickness behavior. NeuroImmunoModulation, 5, 38.Google Scholar
  162. Rabkin, J. G., Wagner, G., & Rabkin, R. (1994). Effects of setraline on mood and immune status in patients with major depression and HIV illness: an open trial. Journal of Clinical Psychiatry, 55, 433–439.PubMedGoogle Scholar
  163. Ranchor, A. V., Bouma, J., & Sanderman, R. (1996). Vulnerability and social class: Differential patterns of personality and social support over the social classes. Personality and Individual Differences, 20(2), 229–237.Google Scholar
  164. Renault, P. E, Hoofnagle, J. H., Park, Y, Mullen, K. D., Peters, M., Jones, D. B., Rustgi, V, & Jones, E. A. (1989). Psychiatric complications of long-term interferon alpha therapy. Archives of Internal Medicine, 147, 1577–1580.Google Scholar
  165. Reul, J. M. H. M., Stec, I., Soder, M., & Holsboer, F. (1993). Chronic treatment of rats with antidepressant amitriptyline attenuates the activity of the hypothalamic-pituitary-adrenocortical system. Endocrinology, 133, 312–320.PubMedGoogle Scholar
  166. Rivier, C. & Rivest, S. (1993). Mechanisms mediating the effects of cytokines on neuroendocrine functions in the rat. In D. J. Chadwick, J. Marsh, & K. Ackrill (Eds.), Corticotropin-Releasing Factor (pp. 204–225). New York: John Weily & Sons.Google Scholar
  167. Robinson, R. G. (1997). Neuropsychiatric consequences of stroke. Annual Review of Medicine, 48, 217–229.PubMedGoogle Scholar
  168. Rodin, G. & Voshart, K. (1986). Depression in the medically ill: An overview. American Journal of Psychiatry, 143, 696–705.PubMedGoogle Scholar
  169. Romanovsky, A. A., Kulchitsky, V. A., Akulich, N. V., Koulchitsky, S. V., Simons, C. T., Sessler, D. I., & Gourine, V. N. (1996). First and second phases of biphasic fever: two sequential stages of the sickness syndrome. American Journal of Physiology, 271, R244–R253.PubMedGoogle Scholar
  170. Rothwell, N. J., Luheshi, G., & Toulmond, S. (1996). Cytokines and their receptors in the central nervous system: Physiology, pharmacology, and pathology. Pharmacology and Therapeutics, 69, 85–95.PubMedGoogle Scholar
  171. Sachar, E. J., Hellman, L., Fukushima, D. K., & Gallaghaer, T. F. (1970). Cortisol production in depressive illness: a clinical and biochemical clarification. Archives of General Psychiatry, 23, 289–298.PubMedGoogle Scholar
  172. Sadovnick, A. D., Remick, R. A., Allen, I, Swartz, E., Lee, I. M. L., Eisen, K., Farquhar, R., Hashimoto, S. A., Hooge, I, Kastrukoff, L. F., Morrison, W., Nelson, J., Ogar, J., & Paty, D. W. (1996). Depression and multiple sclerosis. Neurology, 46, 628–632.PubMedGoogle Scholar
  173. Sakic, B., Denburg, J. A., Denburg, S. D., & Szechtman, H. (1996). Blunted sensitivity to sucrose in autoimmune MRL-lpr mice: A curve shift study. Brain Research Bulletin, 41, 305–311.PubMedGoogle Scholar
  174. Schiffer, R. B. & Babigian, H. M. (1984). Behavioral disorders in multiple sclerosis, temporal lobe epilepsy, and amyotrophic lateral sclerosis: An epidemiological study. Archives of Neurolology, 41, 1067–1069.Google Scholar
  175. Schiffer, R. B. & Wineman, N. M. (1990). Antidepressant pharmacotherapy of depression associated with multiple sclerosis. American Journal of Psychiatry, 147, 1493–1497.PubMedGoogle Scholar
  176. Schneebaom, A. B., Singleton, J. D., & West, S. G. (1991). Association of psychiatric manifestations with antibodies to ribosomal P proteins in systemic lupus erythematosus. American Journal of Medicine, 90, 54–62.Google Scholar
  177. Schobitz, B., De Kloet, E. R., & Holsboer, F. (1994). Gene expression and function of interleukin 1, interleukin 6, and tumor necrosis factor in the brain. Progress in Neurobiology, 44, 391–432.Google Scholar
  178. Schrott, L. M. & Crnic, L. S. (1996). Anxiety behavior, exploratory behavior, and activity in NZB X NZW Fl hybrid mice: role of genotype and autoimmune disease progression. Brain, Behavior, and Immunity, 10, 260–274.PubMedGoogle Scholar
  179. Schubert, D. S. P. & Foliart, R. H. (1993). Increased depression in multiple sclerosis patients: A meta analysis. Psychosomatics, 34, 124–130.PubMedGoogle Scholar
  180. Schwartz, J. A., Speed, N. M., Brunberg, J. A., Brewe, T. L., Brown, M., & Greden, J. F. (1993). Depression in stroke rehabilitation. Biological Psychiatry, 33, 694–699.PubMedGoogle Scholar
  181. Scott, T. F., Nussbaum, P., McConnell, H., & Brill, P. (1995). Measurement of treatment response to sertraline in depressed multiple sclerosis patients using the Carroll scale. Neurological Research, 17, 421–422.PubMedGoogle Scholar
  182. Segall, M. A. & Crnic, L. S (1990). An animal model for the behavioral effects of interferon. Behavioral Neuroscience, 4, 612–618.Google Scholar
  183. Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., & Kirchner, H. (1995). Cytokine production and serum proteins in depression. Scandinavian Journal of Immunology, 41, 534–538.PubMedGoogle Scholar
  184. Seidel, A., Arolt, V., Hunstiger, M., Rink, L., Behnisch, A., & Kirchner, H. (1996). Major depressive disorder is associated with elevated monocyte counts. Acta Psychiatrica Scandinavica, 94, 198–204.PubMedGoogle Scholar
  185. Seilhean, D., Kobayashi, K., He, Y., Uchihara, T., Rosenblum, O., Katlama, C, Bricaire, F., Duyckaerts, C, & Hauw, J. J. (1997). Tumor necrosis factor-alpha, microglia, and astrocytes in AIDS dementia complex. Acta Neuropathologica, 93, 508–517.PubMedGoogle Scholar
  186. Sluzewska, A., Rybakowski, J., Laciak, M., Mackiewicz, A., Sobieska, M., & Wiktorowicz, K. (1995). Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Annals of the New York Academy of Sciences, 762, 474–476.PubMedGoogle Scholar
  187. Sluzewska, A., Rybakowski, J., Bosmans, E., Sobieska, M., Berghmans, R., Maes, M., & Wiktorowicz, K. (1996). Indicators of immune activation in major depression. Psychiatry Research, 64, 161–167.PubMedGoogle Scholar
  188. Smith, B. K. & Kluger, M. J. (1993). Anti-TNF-alpha Antibodies Normalized Body Temperature and Enhanced Food Intake in Tumor-Bearing Rats. American Journal of Physiology, 265, R615–R619.PubMedGoogle Scholar
  189. Smith, A. P., Tyrrell, D. A. J., Al-Nakib, W., Coyle, K. B., Donovan, C. B., Higgins, P. G., & Willman, J. S. (1987). Effects of experimentally induced respiratory virus infections and illness on psychomotor performance. Neurosychobiology, 18, 144–148.Google Scholar
  190. Smith, A. P., Tyrrell, D. A. J., Al-Nakib, W., Coyle, K. B., Donovan, C. B., Higgins, P. G., & Willman, J. S. (1988). The effects of experimentally induced respiratory virus infections on performance. Psychological Medicine, 18, 65–71.PubMedGoogle Scholar
  191. Smith, A. P., Tyrrell, D. A. J., & Barrow, G. I. (1992). Mood and experimentally induced respiratory virus infections and illness. Psychology and Health, 6, 205–212.Google Scholar
  192. Smith, A. P., Thomas, M., Brockman, P., Kent, J., & Nicholson, K. G. (1993). Effect of Influenza B Virus Infection on Human Performance. British Medical Journal, 306, 760–761.PubMedGoogle Scholar
  193. Sommer, N., Loschmann, P. A., Northoff, G. H., Weiler, M., Steinbrecher, A., Steinbach, J. P., Lichtenfels, R., Meyermann, R., Riethmuller, A., Fontana, A., Dichgans, J., & Martin, R. (1995). The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nature Medicine, 1, 244–248.PubMedGoogle Scholar
  194. Song, C. & Leonard, B. E. (1994). An acute phase protein response in the olfactory bulbectomized rat: Effect of sertraline treatment. Medical Science Research, 22, 313–314.Google Scholar
  195. Song, C, Dinan, T., & Leonard, B. E. (1994). Changes in immunoglobulin, complement and acute phase protein levels in depressed patients, and normal controls. Journal of Affective Disorders, 30, 283–288.PubMedGoogle Scholar
  196. Sonti, G., Ilyin, S. E., & Plata-Salaman, C. R. (1996). Anorexia induced by cytokine interactions at pathophysiological concentrations. American Journal of Physiology, 270, R1394–R1402.PubMedGoogle Scholar
  197. Spadaro, F. & Dunn, A. J. (1990). Intracerebroventricular administration of interleukin-1 to mice alters investigation of stimuli in a novel environment. Brain, Behavior, and Immunity, 4, 308–322.PubMedGoogle Scholar
  198. Spriggs, D. R., Sherman, M. L., Michie, H., Arthur, K. A., Imamura, K., Wilmore, D, Frei, E., & Kufe, D. W. (1988). Recombinant human tumor necrosis factor administration as a 24-hr intravenous infusion. A phase I and pharmacologic study. Journal of National Cancer Institute, 80, 1039–1044.Google Scholar
  199. Suzuki, T., Funada, M., Sugano, Y., Misawa, M., Okutomi, T., Soma, G. I., & Mizuno, D. (1994). Effects of a lipopolysaccharide from pantoea agglomerans on the cocaine-induced place preference. Life Sciences, 54, PL75–PL80.PubMedGoogle Scholar
  200. Swiergiel, A. H., Smagin, G. N., & Dunn, A. J. (1996). Influenza virus infection of mice induces anorexia: Comparison with endotoxin and interleukin-1 and the effects of indomethacin. Pharmacology, Biochemistry, and Behavior, 57, 389–396.Google Scholar
  201. Swiergiel, A. H., Smagin, G. N., Johnson, L. J., & Dunn, A. J. (1997). The role of cytokines in the behavioral responses to endotoxin and influenza virus infection in mice: effects of acute and chronic administration of the interleukin-1-receptor antagonist (IL-lra). Brain Research, 77, 696–104.Google Scholar
  202. Takahashi, S., Kapas, L., Fang, J., Seyer, J. M., Wang, Y., & Krueger, J. M. (1996). An interleukin-1 receptor fragment inhibits spontaneous sleep and muramyl dipeptide-induced sleep in rabbits. American Journal of Physiology, 271, R101–R108.PubMedGoogle Scholar
  203. Tilders, F. J. H., Derijk, R. H., Van Dam, A. M., Vincent, V. A. M., Schotanus, K., & Persoons, J. H. A. (1994). Activation of the Hypothalamus-Pituitary-Adrenal Axis by Bacterial Endotoxins—Routes and Intermediates. Psychoneuroendocrinology, 19, 209–232.PubMedGoogle Scholar
  204. Traskman, L., Tybring, G., Asberg, M., Bertilsson, L., & Schalling, D. (1980). Cortisol in the CSF of depressed and suicidal patients. Archives of General Psychiatry, 37, 761–767.PubMedGoogle Scholar
  205. Tueth, M. J. (1995). How to manage depression and psychosis in Alzheimer’s disease. Geriatrics, 50(1), 43–46, 49.PubMedGoogle Scholar
  206. Turnbull, A. V. & Rivier, C. (1995). Regulation of the HPA axis by cytokines. Brain, Behavior, and Immunity, 9, 253–275.PubMedGoogle Scholar
  207. Uehara, A., Sekiya, C, Takasugi, Y, Namiki, M., & Arimura, A. (1989). Anorexia induced by interleukin 1: involvement of corticotropin-releasing factor. American Journal of Phsyiology, 257, R613–R617.Google Scholar
  208. Valentine, A. D., Meyers, C. A., Kling, M. A., Richelson, E., & Hauser, P. (1998). Mood and cognitive side effects in interferon-alpha therapy. Seminars in Oncology, 25(1), 39–47.PubMedGoogle Scholar
  209. Van der Meer, M. J. M., Fred Sweep, C. G. J., Pesman, G. J., Borm, G. F, & Hermus, A. R. M. M. (1995). Synergism between IL-lβ and TNF-α on the activity of the pituitary-adrenal axis and on food intake in rats. American Journal of Physiology, 268, E551–E557.PubMedGoogle Scholar
  210. Walker, L. G., Wesnes, K. P., Heys, S. D., Walker, M. B., Lolley, J., & Eremin, O. (1996). The cognitive effects of recombinant interleukin-2 (rIL-2) therapy: a controlled clinical trial using computerised assessments. European journal of Cancer, 13, 2275–2283.Google Scholar
  211. Walker, L. G., Walker, M. B., Heys, S. D., Lolley, J., Wesnes, K. P., & Eremin, O. (1997). The psychological and psychiatric effects of rIL-2 therapy: a controlled clinical trial. Psychooncology, 6(4), 290–301.PubMedGoogle Scholar
  212. Warren, E. J., Finck, B. N., Arkins, S., Kelley, K. W., Scamurra, R. W., Murtaugh, M. P., & Johnson, R. W. (1997). Coincidental changes in behavior and plasma cortisol in unrestrained pigs after intracerebroventricular injection of tumor necrosis factor-α. Endocrinology, 138, 2365–2371.PubMedGoogle Scholar
  213. Watkins, L. R., Maier, S. F., & Goehler, L. E. (1995a). Cytokine-to-brain communication: A review and analysis of alternative mechanisms. Life Sciences, 57, 1011–1026.PubMedGoogle Scholar
  214. Watkins, L. R., Maier, S. F., & Goehler, L. E. (1995b). Immune activation: the role of pro-inflammatory cytokines in inflammation, illness responses, and pathological pain states. Pain, 63, 289–302.PubMedGoogle Scholar
  215. Weidenfeld, J. & Yirmiya, R. (1996). Effect of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress, Neuroimmunomodulation, 3, 352–357.PubMedGoogle Scholar
  216. Weizman, R., Laor, N., Podliszewski, E., Notti, I., Djaldetti, M., & Bessler, H. (1994). Cytokine Production in Major Depressed Patients Before and After Clomipramine Treatment. Biological Psychiatry, 35, 42–41.PubMedGoogle Scholar
  217. Whitlock, F. A. & Siskind, M. M. (1980). Depression as a major symptom of multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry, 43, 861–865.Google Scholar
  218. Willner, P. (1994). Animal models of depression. In J. A. den Boer & J. M. Sitsen (Eds.), Handbook of depression and anxiety (pp. 291–316). New York: Marcel Dekker, Inc.Google Scholar
  219. Willner, P. (1997). Validity, reliability, and utility of the chronic mild stress model of depression: A 10-year review and evaluation. Psychopharmacology, 134, 319–329.PubMedGoogle Scholar
  220. Wilson, E. O. (1975). Sociobiology: The new synthesis. Cambridge: Harvard University Press.Google Scholar
  221. Wohlman, A., Gallily, R., Yirmiya, R., & Weidenfeld, J. (1997). Characterization of the effect of Mycoplasma fermentans on the hypothalamo-pituitary-adrenal axis. Neuroendocrinology, 66, 221–228.PubMedGoogle Scholar
  222. Wong, M. L., Bongiorno, P. B., Rettori, V., McCann, S. M., & Licinio, J. (1997). Interleukin (IL) Iβ, IL-1 receptor antagonist, IL-10, and IL-13 gene expression in the central nervous system and anterior pituitary during systemic inflammation: Pathophysiological implications. Proceedings of the National Academy of Sciences of the United States of America, 94, 227–232.PubMedGoogle Scholar
  223. Xia, Z., DePierre, J. W., & Nassberger, L. (1996). Tricyclic antidepressants inhibit IL-6, IL-lβ, and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T-cells. Immunobiology, 34, 27–37.Google Scholar
  224. Xiao, L. & Eneroth, P. (1996). Tricyclic antidepressants inhibit human natural killer cells. Toxicology and Applied Pharmacology, 137, 157–162.PubMedGoogle Scholar
  225. Yamada, T. & Yamanaka, I. (1995). Microglial localization of alpha interferon receptor in human brain tissues. Neuroscience Letters, 189, 73–76.PubMedGoogle Scholar
  226. Yehuda, R. & Nemeroff, C. B. (1994). Neuropeptide alterations in affective and anxiety disorders. In J. A. den Boer & J. M. Sitsen (Eds.), Handbook of depression and anxiaty (pp. 543–571). New York: Marcel Dekker, Inc.Google Scholar
  227. Yirmiya R. (1996). Endotoxin produces a depressive-like syndrome in rats. Brain Research, 711, 163–174.PubMedGoogle Scholar
  228. Yirmiya, R. (1997). Behavioral and psychological effects of immune activation: Implications for “depression due to a general medical condition”. Current Opinion in Psychiatry, 10, 470–476.Google Scholar
  229. Yirmiya, R., Rosen, H., Donchin, O., & Ovadia, H. (1994). Behavioral effects of lipopolysaccharide in rats: Involvement of endogenous opioids. Brain Research, 648, 80–86.PubMedGoogle Scholar
  230. Yirmiya, R., Avitsur, R., Donchin, O., & Cohen, E. (1995). Interleukin-1 inhibits sexual behavior in female but not in male rats. Brain, Behavior, and Immunity, 9, 220–33.PubMedGoogle Scholar
  231. Yirmiya, R., Barak, O., Avitsur, R., Gallily, R., & Weidenfeld, J. (1997). Intracerebral administration of Mycoplsma fermentans produces sickness behavior: role of prostaglandins. Brain Research, 749, 71–81.PubMedGoogle Scholar
  232. Zacharko, R. M., Zalcman, S., Macneil, G., Andrews, M., Mendella, P. D., & Anisman, H. (1997). Differential effects of immunologic challenge on self-stimulation from the nucleus accumbens and the substantia nigra. Pharmacology, Biochemistry, and Behavior, 58, 881–886.PubMedGoogle Scholar
  233. Zhu, J., Bengtsson, B. O., Mix, E., Thorell, L. H., Olsson, T., & Link, H. (1994). Effect of monoamine reup-take inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN). lmmunopharmacology, 27(3), 225–244.Google Scholar
  234. Zorzenon, M., Colle, R., Vecchio, D., Bertoli, M., Giavedoni, A., Degrassi, A., Lavaroni, S., & Aguglia, E. (1996). Major depression, viral reactivation, and immune system. European Psychiatry, 11, 332.Google Scholar
  235. Zubareva, O. E., Abdurasulova, I. N., Bluthe, R. M., Dantzer, R., & Klimenko, V. M. (1998). Effects of serotonin synthesis blockade on IL-1 beta actions in the brain of rats. NeuroImmunoModulation, 5, 56.Google Scholar

Copyright information

© Kluwer Academic/Plenum Publishers 1999

Authors and Affiliations

  • Raz Yirmiya
    • 1
  • Joseph Weidenfeld
    • 2
  • Yehuda Pollak
    • 1
  • Michal Morag
    • 1
  • Avraham Morag
    • 3
  • Ronit Avitsur
    • 1
  • Ohr Barak
    • 1
  • 1]Avraham Reichenberg
  • Edna Cohen
    • 1
  • Yehuda Shavit
    • 1
  • Haim Ovadia
    • 2
  1. 1.Department of Psychology, Mount ScopusThe Hebrew University of JerusalemIsrael
  2. 2.Departments of NeurologyHadassah-Hebrew University HospitalEin Karem, JerusalemIsrael
  3. 3.Department of Clinical VirologyHadassah-Hebrew University HospitalEin Karem, JerusalemIsrael

Personalised recommendations